Valuation: Memphasys Limited

Market Cap 15.44M 10.73M 9.45M 8.96M 8.09M 15.24M 1.03B 107M 41.24M 526M 40.31M 39.43M 1.69B P/E 2025
-1.57x
P/E 2026 -3.94x
Enterprise Value 18.5M 12.87M 11.33M 10.73M 9.69M 18.27M 1.23B 128M 49.43M 631M 48.31M 47.26M 2.02B EV / Sales 2025
24,365,123x
EV / Sales 2026 35,157,730x
Free-Float
61.3%
Yield 2025 *
-
Yield 2026 -
3 months-28.57%
6 months+11.11%
Current year-28.57%
1 week 0
Extreme 0.0045
0.01
1 month 0
Extreme 0.004
0.01
Current year 0
Extreme 0.004
0.01
1 year 0
Extreme 0.002999
0.01
3 years 0
Extreme 0.002999
0.01
5 years 0
Extreme 0.002999
0.12
10 years 0
Extreme 0.002999
0.16
Manager TitleAgeSince
Director of Finance/CFO - -
Chief Tech/Sci/R&D Officer - 2021-06-30
Corporate Secretary - 2025-10-07
Director TitleAgeSince
Director/Board Member - 2018-06-06
Director/Board Member - 2025-10-19
Chairman - 2026-05-18
Date Insider Type Main position Quantity % Market Cap. Importance
1/2/23 Buy

Director

1,400,000 0.1459%
1/2/23 Buy

Chief Executive Officer

392,500 0.0409%
1/24/22 Sell

Director

1,350,000 0.1704%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%+25.00%-61.53% 10.73M
-0.67%+1.47%+39.18%+33.36% 250B
-2.02%-0.00%+11.75%-10.70% 156B
-1.35%+2.09%-9.08%+39.12% 144B
-0.52%-2.17%-55.29%-17.33% 63.26B
-2.00%-0.58%+10.99%+24.60% 49.75B
-1.55%+4.23%+34.25%+54.10% 48.58B
-1.00%+0.86%-18.94%-21.93% 47.99B
+2.47%+5.43%-4.18%+40.30% 46.22B
-0.87%+4.47%+46.56%+60.24% 43.17B
Average -0.75%+2.05%+8.02%+14.02% 84.8B
Weighted average by Cap. -1.01%+2.37%+11.70%+21.75%

Financials

2025 2026
Net sales 0.53 0.37 0.32 0.31 0.28 0.52 35.13 3.66 1.41 17.96 1.38 1.35 57.58 0.66 0.46 0.4 0.38 0.34 0.65 43.87 4.57 1.76 22.43 1.72 1.68 71.91
Net income -5.04M -3.5M -3.09M -2.92M -2.64M -4.97M -336M -34.98M -13.46M -172M -13.16M -12.87M -551M -4.1M -2.85M -2.51M -2.38M -2.15M -4.05M -274M -28.49M -10.96M -140M -10.72M -10.48M -448M
Net Debt 4.9M 3.41M 3M 2.85M 2.57M 4.84M 327M 34.04M 13.1M 167M 12.81M 12.53M 536M 3.07M 2.13M 1.88M 1.78M 1.61M 3.03M 204M 21.28M 8.19M 104M 8.01M 7.83M 335M
Logo Memphasys Limited
Memphasys Limited is an Australia-based reproductive biotechnology company. The Company is engaged in developing medical devices, diagnostics, and media with application to assisted reproductive technology (ART) in humans and animals. The Company's product pipeline includes Felix, RoXsta, and AI-Port. Its advanced product, the Felix System, is a patented automated device for quickly and gently separating sperm from a semen sample for use in ART procedures. The Felix device consists of two main components: a console, which supplies electrical power, and a sterile disposable cartridge for sperm isolation and selection. RoXsta is an in-vitro diagnostic device that assesses semen and other bodily fluids for oxidative stress load. RoXsta also has an application as part of a suite of products that can support the animal industry. AI-Port has been developed for the purpose of maintaining the viability of livestock semen for up to seven days at a temperature range of 22 - 25 degrees Celsius.
Employees
24
Date Price Change Volume
26-10-01 A$0.005000 0.00% 514,955
26-09-30 A$0.005000 0.00% 2,421,755
26-09-29 A$0.005000 0.00% 3,765,155
26-09-25 A$0.005000 0.00% 6,699,082
26-09-24 A$0.005000 0.00% 2,515,956